Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Dissertation zum Erwerb des Doktorgrades der Humanbiologie
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität zu München

vorgelegt von
Natascha Jennifer Küpper
aus Mülheim an der Ruhr
2017
Mit Genehmigung der Medizinischen Fakultät der Universität München

Berichterstatter: Prof. Dr. med. Stefan Endres
Mitberichterstatter: Priv. - Doz. Dr. med. vet. Robert Kammerer
Mitbetreuung durch den promovierten Mitarbeiter: Priv. - Doz. Dr. med. Sebastian Kobold
Dekan: Prof. Dr. med. dent. Reinhard Hickel

Tag der mündlichen Prüfung: 20.02.2017
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

1. Table of Content
   1. Table of Content ............................................................................................................ 4

2. Summary .......................................................................................................................... 7

3. Introduction ....................................................................................................................... 9
   3.1. Physiology of interleukin-22 ......................................................................................... 9
       3.1.1. Cellular sources of IL-22 .................................................................................... 9
       3.1.2. IL-22 receptor-1 and its signaling pathway ......................................................... 10
       3.1.3. Physiological functions of IL-22 ......................................................................... 11
       3.1.4. Pathophysiological functions of IL-22 ................................................................. 12
       3.1.5. Influence of cytokines on IL-22 signaling ............................................................ 14
       3.1.6. Role of IL-22 in carcinogenesis ......................................................................... 16
       3.1.7. Role of IL-22 in colorectal cancer development ................................................ 17
   3.2. Objectives ................................................................................................................... 19

4. Material and Methods ..................................................................................................... 20
   4.1. Materials .................................................................................................................... 20
       4.1.1. Chemicals and reagents ..................................................................................... 20
       4.1.2. Cell culture reagents and media ......................................................................... 20
       4.1.3. Western blot buffers ......................................................................................... 22
       4.1.4. Kits .................................................................................................................... 22
       4.1.5. Cytokine ELISA sets ......................................................................................... 23
       4.1.6. Enzymes ............................................................................................................ 23
       4.1.7. Cytokines ............................................................................................................ 23
       4.1.8. Antibodies ......................................................................................................... 23
           4.1.8.1. Western blot antibodies .............................................................................. 23
           4.1.8.2. FACS antibodies ....................................................................................... 24
       4.1.9. Primers for qRT-PCR ....................................................................................... 25
       4.1.10. Human cell lines ............................................................................................... 25
       4.1.11. Equipment ........................................................................................................ 26
       4.1.12. Patient samples ................................................................................................. 27
       4.1.13. Computer programs .......................................................................................... 28
   4.2. Methods ...................................................................................................................... 29
       4.2.1. Molecular biology ............................................................................................... 29
           4.2.1.1. Isolation of cytoplasmatic RNA .................................................................... 29
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

6. Discussion ........................................................................................................................................ 48
6.1. IL-22 expression in human PBMC from healthy donors ............................................................. 48
6.2. Expression of IL-22 in colorectal cancer tissue ...................................................................... 49
6.3. Expression of IL-22-R1 and activation of STAT3 ................................................................ 51
6.3.1. IL-22 induces VEGF, IL-10 and proliferation in Colo205 cells ............................................. 52
6.4. Crosstalk of IL-22 pathway with signaling of IFN-γ and TNF-α .............................................. 53
6.4.1. IL-22 inhibits IFN-γ-induced CCL22 secretion in HT29 cells .......................................... 54
6.4.1.1. IL-22 and TNF-α synergistically induce CCL22 and in HT29 cells ......................... 55
6.5. Conclusion and perspectives .................................................................................................. 56

7. References ........................................................................................................................................ 57

8. Appendices ....................................................................................................................................... 69
8.1. Abbreviations ............................................................................................................................. 69
8.2. Publications ................................................................................................................................... 71
8.3. Acknowledgements .................................................................................................................... 73
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

2. Summary

Interleukin-22 (IL-22) is a unique cytokine produced by immune cells and acting exclusively on IL-22 receptor-1 (IL-22-R1) positive epithelial cells. IL-22 plays a central role in epithelial regeneration and contributes to pathogen clearance. In contrast, the proliferation enhancing effects of IL-22 may be used by cancer cells to promote and sustain their growth. This has been shown in genetically modified mouse strains with spontaneous development of colorectal cancer.

The cellular sources of IL-22 in tumor tissue are not yet fully identified.

In a pilot study with tumor tissue of patients with colorectal cancer, we could identify CD3⁺CD4⁺ T cells that produce IL-22. This confirms findings of other groups published in recent years. Peripheral T cells from healthy donors only contained low frequencies of IL-22 producing CD3⁺CD4⁺ cells. Upon stimulation, IL-22 induced STAT3 phosphorylation and proliferation of human colon cancer cell lines. In one cell line, we could also show the induction of the cytokines IL-10 and VEGF. IL-22 suppressed IFN-γ-induced synthesis of the chemokine CCL22 in HT29 cells while enhancing TNF-α-induced expression of CCL22 in the same cell line. This indicates differential effects of IL-22 on IFN-γ- and TNF-α-signaling. IFN-γ as well as TNF-α led to IL-22-R1 upregulation in human colon cancer cell lines.

In summary, we find evidence that in tumor tissue CD3⁺CD4⁺ T cells produce IL-22. IL-22 acts directly on cells of colorectal cancer cell lines. It enhances their proliferation. IL-22 presumable serves as a mediator in the genesis of colorectal cancer and a potential therapeutic target.
Zusammenfassung

Interleukin-22 (IL-22) ist ein einzigartiges Zytokin welches von Immunzellen produziert wird und exklusiv auf IL-22-Rezeptor (IL-22-R1) positive epitheliale Zellen wirkt. IL-22 spielt eine zentrale Rolle in der epithelialen Regeneration und trägt zur Pathogenbeseitigung bei. Im Gegensatz dazu könnten die Effekte von IL-22 von Krebszellen benutzt werden um ihr Wachstum zu fördern. Dies wurde in genetisch modifizieren Mauslinien mit spontaner Entwicklung von Kolonkarzinomen nachgewiesen.

Die zellulären Quellen von IL-22 im Tumorgewebe sind noch nicht vollständig identifiziert.


Zusammenfassend finden wir Hinweise, dass im Tumorgewebe IL-22 von CD3⁺CD4⁺ T Zellen produziert wird. IL-22 wirkt direkt auf kolorektale Karzinomzellen. Es steigert deren Proliferation. IL-22 bildet vermutlich einen Mediator in der Genese von kolorektalen Karzinomen und ein potenzielles therapeutisches Target.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

3. Introduction
3.1. Physiology of interleukin-22

Interleukin-22 (IL-22) is a member of the interleukin-10 (IL-10) family of cytokines which also comprises IL-10, IL-19, IL-20, IL-24, IL-26, IL-28α, IL-28β, and IL-29 (Wolk et al, 2010). IL-22 was first described in 2000 as a secreted α-helical protein in IL-9-stimulated murine BW5147 T lymphoma cells (Dumoutier et al, 2000).

3.1.1. Cellular sources of IL-22

IL-22 is expressed by a number of immune cells of the innate and adaptive immune system. The cellular sources of IL-22 are immune cells. In general T cells and innate lymphoid cells are considered to be the major cellular sources of IL-22 (Sabat et al, 2014). CD4⁺ T cells, including Th-1 cells, Th-17 cells and Th-22 cells produce IL-22 (Duhen et al, 2009; Witte et al, 2010; Wolk et al, 2002).

Th-17 cells produce IL-22 as an effector cytokine together with IL-17 (Chung et al, 2006; Liang et al, 2006; Ouyang et al, 2008). The retinoic-acid-related orphan nuclear receptor RORγt is the master regulator of Th-17 cells (Ivanov et al, 2006). Among the factors that drive Th-17 differentiation and IL-17 expression, IL-6 and IL-23 induce IL-22 expression while transforming growth factor-β (TGF-β) antagonizes IL-22 induction (Rutz et al, 2011).

Th-22 cells are defined as expressing the chemokine receptors CCR4, CCR6, CCR10 and producing IL-22 but not any other known T-helper-prototypical cytokine, such as IL-17 or IFN-γ. Th-22 cells have a high expression of the aryl hydrocarbon receptor (AHR) but a low expression of RORγt and T-bet (Duhen et al, 2009; Trifari et al, 2009). In vitro, Th-22 cells may develop in interaction with plasmacytoid dendritic cells (pDCs) with IL-6 und TNF-α as driving factors (Duhen et al, 2009). Activation of the aryl hydrocarbon receptor (AHR) is important for IL-22 production in CD4⁺ memory T cells suggesting a role for AHR-ligands in Th-22 polarization (Stockinger et al, 2009; Trifari et al, 2009; Veldhoen et al, 2009). In addition, it has been reported that IL-23 stimulation is a prerequisite for the IL-22 production of CD4⁺ T cells (Zheng et al, 2007). IL-1β has been described to further promote Th-22 differentiation (Ivanova & Orekhov, 2015).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

In addition to CD4\(^+\) T cells, CD8\(^+\) T cells (Nogales et al, 2009) are also capable of producing IL-22 (Liu et al, 2011b; Ortega et al, 2009). Innate immune cells also belong to the IL-22 producers: IL-22 is expressed by certain natural killer (NK) cell subsets, natural killer T (NKT) cells (Goto et al, 2009), γδ T cells (Martin et al, 2009), LTi (lymphoid tissue inducer) cells (Sonnenberg et al, 2011) and LTI-like (lymphoid tissue-like inducer) cells (Takatori et al, 2009).

Although IL-22 is produced by the above described immune cells it does not act on those. IL-22 is a unique cytokine, produced by immune cells, which does not act on cells of hematopoietic origin but on epithelial cells via the Janus kinase (JAK) - signal transducer and activators of transcription (STAT) pathway (Wolk et al, 2010).

### 3.1.2. IL-22 receptor-1 and its signaling pathway

IL-22 acts via a heterodimeric transmembrane receptor, composed of the IL-22-receptor-1 (IL-22-R1) and the IL-10-receptor-2 (IL-10-R2) (Wu et al, 2008). The IL-22-R1 chain holds the docking site for STAT signal molecules. The IL-10-R2 component is ubiquitously expressed due to its function as part of several cytokine receptors. Cellular responsiveness to IL-22 is thus determined by the expression of IL-22-R1. IL-22-R1 is not expressed on cells of hematopoietic origin but on cells of epithelial and endothelial origin (Wolk et al, 2002; Wolk et al, 2004).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

**Figure 1: IL-22 signaling cascade.** IL-22 signals via the activation of the Jak-STAT pathway. Receptor-associated tyrosine kinases Jak1 and Tyk2 are phosphorylated leading to phosphorylation of IL-22-R1 pre-associated STAT3. STAT3 dimerizes and translocates to the nucleus leading to transcription of target genes (modified from Wolk et al, 2010).

IL-22 activates the JAK-STAT pathway. First phosphorylation of the receptor associated tyrosine kinases JAK1 and TYK2 takes place which in turn phosphorylate specific receptor tyrosine residues serving as docking sites for sarcoma homology 2 (SH2) domains of STAT3. Subsequently, receptor-docked STAT3, is phosphorylated itself, dimerizes and translocates into the nucleus. There, pSTAT3 can bind responsive elements and regulate gene expression (Lejeune et al, 2002).

### 3.1.3. Physiological functions of IL-22

Unlike most interleukins, IL-22 does not directly act on immune cells (Wolk et al, 2004), but regulates functions of cells of the body barriers (Sabat et al, 2014) where IL-22-R1 is expressed. The expression pattern identifies the main target cells: the digestive tract.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

(pancreas, small intestine, liver, colon), the respiratory system (lung, trachea), kidney and skin (Wolk et al, 2004).

The physiological function of IL-22 is to protect tissues from damage and to enhance their regeneration. In many of the above-mentioned cells IL-22 induces anti-microbial proteins and chemokines. Induction of an epithelial innate immune response directed against extracellular pathogens is one example of the protective function of IL-22.

In the skin, IL-22 mainly targets keratinocytes (Wolk et al, 2009; Wolk et al, 2004). There, IL-22 signaling has been shown to control innate immunity by upregulating the expression of β-defensins 2 and 3 as well as the anti-microbial heterodimer S100A8/9 (Kolls et al, 2008; Wolk et al, 2004; Wolk et al, 2006).

In bronchial epithelial cells IL-22 upregulates G-CSF and antimicrobial proteins such as BD2, S100A7 and A100A12 and the chemokines CXCL1 and CXCL5. IL-22 promotes epithelial regeneration and reduction of *K. pneumoniae* growth (Aujla et al, 2008).

IL-22 also acts on the gastrointestinal tract. In the pancreas, the organ with the highest IL-22-R1 expression, it has been shown that IL-22 induced osteopontin and pancreatitis-associated protein (PAP) 1/RegIIIα (Aggarwal et al, 2001). In human intestinal epithelial cells IL-22 increased the expression of BD2 and IL-8 (Brand et al, 2006). The impact of IL-22 in the defense against infections with bacteria of the intestinal tract has been shown in a number of studies: IL-22 induces the expression of anti-bacterial peptides namely: β-defensins, RegIIIβ, and RegIIIγ, S100A7, S100A8 and S100A9 (Liang et al, 2006; Wolk et al, 2004; Wolk et al, 2006). The release of anti-bacterial peptides can be increased by the combination of IL-22 and IL-17 (Liang et al, 2006).

3.1.4. **Pathophysiological functions of IL-22**

IL-22 is upregulated in a number of chronic inflammatory and autoimmune diseases generating the hypothesis that IL-22 may be disease promoting in this context. The production of IL-22 by T cells may indicate that IL-22 is involved in the pathogenesis of T
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

cell-mediated diseases such as psoriasis, rheumatoid arthritis (RA) or inflammatory bowel disease (IBD).

The impact on keratinocytes is important in psoriasis and atopic skin pathogenesis where IL-22 has been found to be a key mediator. In atopic skin IL-22 has been found to be mainly produced by Th-22 cells (Nograles et al, 2009). In a psoriasis-like disease model it has been shown that upon treatment of mice with IL-22 neutralizing antibodies the expression of Th-17 cytokines was reduced as well as the recruitment of inflammatory infiltrates. In addition, this treatment prevented development of disease (Ma et al, 2008). In an imiquimod-induced mouse model of skin inflammation, skin lesions that are induced in wild-type mice were almost absent in IL-22-deficient mice or in mice treated with an IL-22 blocking antibody (Van Belle et al, 2012).

IL-22 is found in large quantities in the inflamed regions of the colonic mucosa in ulcerative colitis and Crohn’s disease, which are predisposing diseases for colorectal cancer (Andoh et al, 2005). In IBD CD4+ IL-22 expressing T cells have been shown to be present in the inflamed regions of the gut: In active Crohn’s disease and ulcerative colitis IL-22 is abundantly found in the submucosa or in the lamina propria, respectively (Andoh et al, 2005; Brand et al, 2006). Furthermore, systemic IL-22 levels are increased in patients with Crohn’s disease (Wolk et al, 2007). One study showed that intestinal tissue from patients with IBD expressed significantly less AHR compared to controls. Conversely, there are experimental data that IL-22 can protect mice from IBD. This protection was mediated by CD4 T cells and IL-22 expressing NK cells (Zenewicz et al, 2008). In a mouse model it has been shown that AHR induced IL-22 and inhibited inflammation in the gastrointestinal tract (Monteleone et al, 2011).

Th-22 cells are increased in the peripheral blood of patients suffering from rheumatoid arthritis (RA) and levels of IL-22 are increased in their plasma, which correlates with disease activity (da Rocha et al, 2012; Leipe et al, 2011; Zhang et al, 2011b; Zhang et al, 2012a). Fibroblasts from patients with RA that show high concentrations of IL-22 increased proliferation and the release of CCL2, which attracts monocytes (Ikeuchi et al, 2005). Further, IL-22 deficient mice showed a less severe form of arthritis as compared to wild-type mice, indicating the disease-promoting role of IL-22 (Geboes et al, 2009).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

3.1.5. Influence of cytokines on IL-22 signaling

IL-22 is generally secreted with other cytokines. IL-22 effects as well as IL-22 expression are influenced by other cytokines like IFN-α, IFN-γ, TNF-α and IL-17 (Eyerich et al, 2009; Guilloteau et al, 2010; Liang et al, 2006; Pennino et al, 2013).

IL-22 can decrease the responsiveness of epithelial cells to T cell–mediated cytotoxicity by counteracting the IFN-γ–induced expression of MHC-I (Pennino et al, 2013). IFN-α, IFN-γ and TNF-α induce increased responsiveness of keratinocytes towards IL-22 by upregulation of IL-22-R1 and IL-10-R2 (Kunz et al, 2006; Tohyama et al, 2012).

Figure 2: Crosstalk of IL-22 and IFN-γ in the context of effects on epithelial cells. IFN-γ induces chemokines in epithelial and cancer cells, upregulates MHC-I and IL-22-R1 (Kunz et al, 2006; Pennino et al, 2013). IL-22 antagonizes chemokine upregulation and upregulation of MHC-I by IFN-γ (Pennino et al, 2013). Green arrows indicate effects of IFN-γ, red - indicate antagonistic effects of IL-22.
IL-22 and TNF-α are both released by Th-22 cells (Eyerich et al, 2009). IL-22 enhances TNF-α-induced secretion of complement factors C1r and C1s, peptides S100A7 and HBD-2 and chemokines CXCL-9, CXCL-10 and CXCL-11 (Eyerich et al, 2011). Expression of IL-22-R1 in both keratinocytes and dermal fibroblasts is induced by TNF-α (Wolk et al, 2009; Wolk et al, 2004). In keratinocytes, IL-22 may also synergize with IL-17 and IFN-γ in inducing keratin 17 expression which indicates that IL-22 is involved in a positive feedback loop where keratin 17 induces the proliferation and activation of T cells (Zhang et al, 2012b).

One study showed that the function of IL-22 in a bleomycin-induced lung inflammation model differed in the presence or absence of IL-17. In the presence of IL-17, IL-22 led to more inflammation whereas in the absence of IL-17, IL-22 exerted tissue-protective functions (Sonnenberg et al, 2010).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

3.1.6. Role of IL-22 in carcinogenesis

The proliferative, tissue regenerating and pro-inflammatory properties of IL-22 raised the question of a potential involvement in cancer of this particular cytokine where its effects may be tumor-promoting.

Table 1: Overview of literature connected to the role of IL-22 in cancer

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Key messages of publication</th>
</tr>
</thead>
</table>
| Lymphoma          | • Anaplastic large cell lymphoma shows aberrant expression of IL-22-R1 (Bard et al, 2008) as well as mantle cell lymphoma (Gelebart et al, 2011)  
|                   |     • IL-22 stimulation of mantle cell lymphoma cell lines leads to increase of STAT3 activation and cell proliferation (Gelebart et al, 2011)  
|                   |     • Patients suffering from cutaneous T cell lymphoma show increased levels of IL-22 in lesional skin, elevate IL-22 serum levels correlate with severity of disease (Miyagaki et al, 2011) |
| Gastric cancer    | • Increased circulating Th-22 and Th17 cells of patients are associated with tumor progression (Liu et al, 2012)  
|                   |     • Increased intratumoral CD4⁺IL-22⁺ T cells and Th-22 cells are linked to tumor progression and lower patient survival (Zhuang et al, 2012)  
|                   |     • IL-22 produced by cancer-associated fibroblasts promotes cancer cell invasion (Fukui et al, 2014) |
| Pancreatic cancer | • IL-22 stimulated production of vascular endothelial growth factor (VEGF) and anti-apoptotic proteins (Curd et al, 2012).  
|                   |     • Frequencies of CD4⁺IL-22⁺ cells and Th-22 cells were significantly increased in pancreatic cancer tissue compared to peripheral blood and healthy controls, intratumoral IL-22 levels and frequencies of Th-22 and CD4⁺ IL-22-producing cells has been linked to progression of disease (Xu et al, 2014)  
|                   |     • High expression of IL-22 and IL-22-R is linked to poor patient prognosis (Wen et al, 2014) |
Hepatocellular carcinoma

- IL-22 in the tumor microenvironment, leads to increased growth, inhibition of apoptosis and promotion of metastases (Jiang et al, 2011)
- Th-22 are associated with heptatocellular carcinoma development (Qin et al, 2014)
- IL-22 serum levels are a negative prognostic factor (Waidmann et al, 2014)

Renal cancer

- IL-22 dose-dependently suppresses renal cell carcinoma cells in vitro and induced growth inhibition of renal carcinoma cell-bearing mouse xenografts (Zhang et al, 2011a)

Kaposi sarcoma

- IL-22-R1 transcript levels are downregulated in Kaposi’s Sarcoma (Su et al, 2011)

Lung cancer

- The number of IL-22 producing Th-22 cells is increased in malignant pleural effusion (Ye et al, 2012).
- Autocrine production of IL-22 may contribute to human lung cancer cell survival and resistance to chemotherapy through the upregulation of anti-apoptotic proteins (Zhang et al, 2008)
- IL-22 was frequently expressed in human lung cancer tissue (Kobold et al, 2013)

Skin cancer

- Proliferation and migration of human skin basal cell carcinoma and squamous-cell carcinoma cell were increased by IL-22, IL-22 induced STAT3 pathway and the antiapoptotic AKT protein, IL-22 enhanced tumor growth in nude mice injected with basal cell carcinoma cell lines (Nardinocchi et al, 2015)

3.1.7. Role of IL-22 in colorectal cancer development

Chronic mucosal inflammation predisposes patients to colorectal cancer development (Grivennikov et al, 2010). Patients suffering from ulcerative colitis and Crohn’s disease have a higher risk of developing colorectal cancer (Bernstein et al, 2001; Schottenfeld & Beebe-Dimmer, 2006). However, it is still poorly understood what type of immune cells and cytokines trigger the development from chronic inflammation to colorectal cancer. IL-22 is considered to play a crucial role in this process (Kirchberger et al, 2013).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Experimental models of inflammation-associated colorectal cancer development suggest that inflammatory cell-derived cytokines (including IL-22) directly or indirectly stimulate the growth of cancer cells (Grivennikov et al, 2009; Huber et al, 2012; Hyun et al, 2012; Kirchberger et al, 2013). IL-22 seems to drive the development of colorectal cancer via the activation of STAT3 (Lim & Savan, 2014). Forced expression of IL-22 using retroviral transduction of Colon-26 carcinoma cell lines had no impact on tumor growth or metastasis but prolonged survival of inoculated mice (Nagakawa et al, 2004). Another study found an association of colorectal cancer and the human IL22 rs1179251 G allele with a 52 % increase in risk of developing colorectal cancer by individuals with at least one of these alleles (Thompson et al, 2010). IL-22 enhances iNOS expression and contributes to tumorigenesis in colorectal cancer (Takahashi et al, 1997; Ziesche et al, 2007). Oxidative activity mediated by IL-22 is required for activation of STAT3. An oxidative inflammatory microenvironment containing IL-22 increases the risk of tumor development (Bansal et al, 2013).

Higher IL-22 serum levels are found in chemotherapy-resistant patients in contrast to chemotherapy-sensitive patients and IL-22 treatment of colorectal cancer cell lines enhances chemotherapy-resistance of these cancer cells (Wu et al, 2013).

As a further line of evidence for the importance of IL-22 in colorectal cancer development, the lack of the natural antagonist to IL-22: IL-22-binding protein (IL-22BP) leads to enhanced colitis-associated colon carcinogenesis (Huber et al, 2012). In this setting, IL-22 secretion is driven by infiltrating leukocytes, as peripheral leukocytes are weaker producers of IL-22. These IL-22 producing tumor-infiltrating lymphocytes enhance tumor growth and metastasis in a xenograft mouse model via STAT3 activation (Jiang et al, 2013). In colorectal cancer, CD4⁺ T cells seem to be the main source of IL-22. IL-22 promoted activation of STAT3 induces the methyltransferase DOT1L. The DOT1I complex in turn induces the core stem cell genes Sox2, Nanog and Pou5F1, leading to the conclusion that IL-22 promotes colorectal cancer stemness (Kryczek et al, 2014).

Th-22 accumulation is linked to colorectal cancer development. IL-22 expression is significantly higher in tumor tissue than in peritumoral tissue (Huang et al, 2015).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

3.2. Objectives

Our group could previously show increased proliferation and STAT3 phosphorylation in human lung cancer cell lines upon IL-22 stimulation (Kobold et al, 2013). This study seeks to gain a better understanding of the effects of IL-22 and of IL-22 producing T cells on colorectal cancer cells.

Tumor-infiltrating lymphocytes are important in colorectal cancer biology. Thereby, T cells producing tumor promoting IL-22 are significant players in this population. In addition, the exact impact of IL-22 at the cellular and sub cellular level in colorectal cancer is incompletely understood.

To gain further understanding of IL-22 in colorectal cancer, IL-22-producing T cells will be analyzed:

• Proportions of IL-22\(^+\) among Th-1, Th-17 and Th-22 cells in healthy human PBMC
• Proportions of IL-22\(^+\) among Th-1, Th-17, Th-22 and CD8\(^+\)IL-22\(^+\) T cells in tissue taken from patients with cancer of the colon or of the rectum

Additionally, the effect of IL-22 will be studied on human colorectal cancer cell lines:

• Ability to phosphorylate STAT3 in colorectal cancer cells proliferation upon IL-22 stimulation
• Impact of IL-22 on cytokine release from colorectal cancer cells
• Effect of IL-22 on IFN-γ as well as on TNF-α
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4. Material and Methods
4.1. Materials

4.1.1. Chemicals and reagents

- Bovine serum albumine (BSA) Sigma Aldrich, Steinheim, Germany
- Brefeldin A Sigma Aldrich, Steinheim, Germany
- Dimethyl sulfoxide (DMSO) Sigma Aldrich, Steinheim, Germany
- Dulbecco’s PBS (1x) PAA, Pasching, Austria
- Ethylenediamine tetraacetic acid (EDTA) Sigma Aldrich, Steinheim, Germany
- FACSFlow, FACSSafe Becton Dickinson, San Jose, USA
- Fixable Viability Dye eFluor® 780 eBioscience
- Ionomycin Sigma Aldrich, Steinheim, Germany
- Lysis buffer Cell Signaling, USA
- Isopropanol (70 Vol %) Apotheke Innenstadt, LMU Munich
- Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich, Steinheim, Germany
- Propidium iodide Sigma Aldrich, Steinheim, Germany
- Protease inhibitor cocktail Sigma-Aldrich, Steinheim, Germany
- Rotiphorese® NF-Acrylamid/Bis-Lösung Roth, Karlsruhe, Germany
- 30 % (29:1) Sigma Aldrich, Steinheim, Germany
- Trypan blue Roth, Karlsruhe, Germany
- Tween® 20 Roth, Karlsruhe, Germany

4.1.2. Cell culture reagents and media

- Dulbecco’s modified Eagle’s medium (DMEM) PAA, Pasching, Austria
- Fetal calf serum (FCS) GibcoBRL (invitrogen), Karlsruhe, Germany
- L-glutamine 200 mM PAA, Pasching, Austria
- McCoy’s 5A (modified) Invitrogen, Carlsbad, USA
- NEM-NEAA (non-essential amino acids) GibcoBRL (invitrogen), Karlsruhe, Germany
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Opti-MEM® I Reduced Serum Medium GibcoBRL (invitrogen), Karlsruhe, Germany
1 x PBS PAA, Pasching, Austria
Phosphate-buffered saline (PBS) PAA, Pasching, Austria
Penicillin plus streptomycin (100 x) PAA, Pasching, Austria
Roswell Park Memorial Institute (RPMI) PAA, Pasching, Austria
1640 medium PAA, Pasching, Austria
Sodium pyruvate PAA, Pasching, Austria

Disposable plastic equipment for cell culture experiments were purchased from Becton Dickinson (Heidelberg, Germany), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, Germany), Greiner (Frickenheimen, Germany) or Sarstedt (Numbrecht, Germany).
### 4.1.3. Western blot buffers

**Table 2: Western blot buffers**

<table>
<thead>
<tr>
<th>Buffer Type</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Separating gel buffer (4-fold) pH 8.5</td>
<td>600 ml H₂O&lt;br&gt;182 g tris hydrochloride HCl to pH 8.8&lt;br&gt;4 g SDS</td>
</tr>
<tr>
<td>Stackin g gel buffer (4-fold) pH 6.8</td>
<td>300 ml H₂O&lt;br&gt;30.25 g tris hydrochloride HCl to pH 6.8&lt;br&gt;H₂O to 500 ml&lt;br&gt;2 g SDS</td>
</tr>
<tr>
<td>SDS-PAGE running buffer (10-fold)</td>
<td>0.25 M Tris&lt;br&gt;2 M Glycin&lt;br&gt;1 % SDS&lt;br&gt;pH 8.3</td>
</tr>
<tr>
<td>Wet transfer buffer</td>
<td>25 mM Tris&lt;br&gt;190 mM Glycin&lt;br&gt;20 % (v/v) Methanol&lt;br&gt;pH 8.0</td>
</tr>
<tr>
<td>Wash buffer (10-fold) pH 7.8</td>
<td>261.4 g tris HCl&lt;br&gt;53.99 tris&lt;br&gt;876.6 g NaCl&lt;br&gt;100 ml tween-20&lt;br&gt;H₂O to 10000 ml</td>
</tr>
<tr>
<td>Blocking solution</td>
<td>5 % milk powder in wash buffer</td>
</tr>
<tr>
<td>Laemmlı buffer (6-fold)</td>
<td>1.2 g SDS&lt;br&gt;0.06 g bromphenol blue&lt;br&gt;4.7 ml glycerol&lt;br&gt;1.2 ml tris pH 6.8 (0.5 M)&lt;br&gt;4.1 ml H₂O&lt;br&gt;0.939 g DTT</td>
</tr>
</tbody>
</table>

### 4.1.4. Kits

- InviTrap® Spin Cell RNA Mini Kit
- Stratec
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.1.5. Cytokine ELISA sets

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IL-22</td>
<td>R &amp; D Systems, Minneapolis, USA</td>
</tr>
<tr>
<td>Human IL-10</td>
<td>R &amp; D Systems, Minneapolis, USA</td>
</tr>
<tr>
<td>Human VEGF</td>
<td>R &amp; D Systems, Minneapolis, USA</td>
</tr>
</tbody>
</table>

4.1.6. Enzymes

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagenase D</td>
<td>Roche, Mannheim, German</td>
</tr>
<tr>
<td>DNase II</td>
<td>Roche, Mannheim, Germany</td>
</tr>
<tr>
<td>Trypsin (10 x)</td>
<td>PAA, Pasching, Germany</td>
</tr>
</tbody>
</table>

4.1.7. Cytokines

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant human IL-22</td>
<td>Peprotech</td>
</tr>
<tr>
<td>Recombinant human IFN-γ</td>
<td>Peprotech</td>
</tr>
<tr>
<td>Recombinant human TNF-α</td>
<td>Peprotech</td>
</tr>
</tbody>
</table>

4.1.8. Antibodies

4.1.8.1. Western blot antibodies

<table>
<thead>
<tr>
<th>Description</th>
<th>Isotype</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse IL-22 Ra1 antibody</td>
<td>Rat IgG2A</td>
<td>496504</td>
<td>R&amp;D Systems</td>
</tr>
<tr>
<td>β-actin (C4) sc-47778 HRP</td>
<td>Mouse IgG1</td>
<td>C4</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Phospho-Stat3 (Thyr705)</td>
<td>Mouse IgG2b</td>
<td>B-7</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Stat3</td>
<td>Mouse IgG1</td>
<td>F-2</td>
<td>Santa Cruz</td>
</tr>
</tbody>
</table>
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

### Table 4: Secondary antibodies

<table>
<thead>
<tr>
<th>Description</th>
<th>Isotype</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goat anti-rabbit IgG HRPsc-2301</td>
<td>Goat IgG</td>
<td>Polyclonal</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Goat anti-rat IgG HRP sc-2006</td>
<td>Goat IgG</td>
<td>Polyclonal</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Anti-Mouse IgG, HRP-linked antibody</td>
<td>Horse IgG</td>
<td>Polyclonal</td>
<td>Cell signaling</td>
</tr>
</tbody>
</table>

### 4.1.8.2. FACS antibodies

#### Table 5: Directly conjugated FACS antibodies

<table>
<thead>
<tr>
<th>Description</th>
<th>Isotype</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annexin V</td>
<td>Chicken recombinant</td>
<td>n.a.</td>
<td>Immunotools</td>
</tr>
<tr>
<td>Anti-Human IL-17A eFluor® 450</td>
<td>Mouse IgG1, κ</td>
<td>eBio64DEC17</td>
<td>eBioscience</td>
</tr>
<tr>
<td>Anti-human PE/Cy7 IL-17A antibody</td>
<td>Mouse IgG1, κ</td>
<td>BL168</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Anti-human APC CD3 antibody</td>
<td>Mouse IgG2a, κ</td>
<td>OKT3</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Anti-human IL-22 PE</td>
<td>Mouse IgG1, κ</td>
<td>22URTI</td>
<td>eBioscience</td>
</tr>
<tr>
<td>Anti-human APC IFN-γ antibody</td>
<td>Mouse IgG1, κ</td>
<td>4S.B3</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Anti-human PerCP/Cy5.5 IFN-γ antibody</td>
<td>Mouse IgG1, κ</td>
<td>4S.B3</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Anti-human FITC CD4 antibody</td>
<td>Mouse IgG2b, κ</td>
<td>OKT4</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Anti-Human CD8a eFluor® 450</td>
<td>Mouse IgG2a</td>
<td>OKT8</td>
<td>eBioscience</td>
</tr>
<tr>
<td>Mouse IgG1, κ Isotype Control PE/Cy7</td>
<td>Mouse (BALB/c) IgG1, κ</td>
<td>MOPC-21</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Mouse IgG1, κ Isotype Control PerCP/Cy5.5</td>
<td>Mouse (BALB/c) IgG1, κ</td>
<td>MOPC-21</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Mouse IgG1 K Isotype Control PE</td>
<td>Mouse IgG1, kappa</td>
<td>P3.6.2.8.1</td>
<td>eBioscience</td>
</tr>
<tr>
<td>Mouse IgG1 K Isotype Control eFluor® 450</td>
<td>Mouse IgG1, kappa</td>
<td>P3.6.2.8.1</td>
<td>eBioscience</td>
</tr>
</tbody>
</table>
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.1.9. Primers for qRT-PCR

<table>
<thead>
<tr>
<th>Description</th>
<th>Sequence 5’-3’</th>
<th>Primer efficiency</th>
<th>Molecular Probe #</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL20 forward</td>
<td>5’- GCT GCT TTG ATG TCA GTG CT-3’</td>
<td>1,809</td>
<td>39</td>
</tr>
<tr>
<td>CCL20 backward</td>
<td>5’- GCA GTC AAA GTT GCT TGC TG-3’</td>
<td>1,926</td>
<td>13</td>
</tr>
<tr>
<td>CCL22 forward</td>
<td>5’- CCC CCT GAC CCC TCT AAC -3’</td>
<td>1,952</td>
<td>73</td>
</tr>
<tr>
<td>CCL22 backward</td>
<td>5’- GGA ACA GGA CCC TCT GAC TG-3’</td>
<td>2,042</td>
<td>6</td>
</tr>
<tr>
<td>HPRT forward</td>
<td>5’-CGA GCA AGA CGT TCA GTC CT-3’</td>
<td>2,130</td>
<td>28</td>
</tr>
<tr>
<td>HPRT backward</td>
<td>5’-TGA CCT TGA TTT ATT TTG CAT ACC-3’</td>
<td>2,104</td>
<td>34</td>
</tr>
<tr>
<td>IL-22 forward</td>
<td>5’- CAACAGCTAAGCACATGTCA -3’</td>
<td>1,809</td>
<td>39</td>
</tr>
<tr>
<td>IL-22 backward</td>
<td>5’- ACT GTG TCC AGC TTT TGC -3’</td>
<td>1,926</td>
<td>13</td>
</tr>
<tr>
<td>IL-22-R1 forward</td>
<td>5’-CACCCTCCAACCTCCC TGA-3’</td>
<td>1,952</td>
<td>73</td>
</tr>
<tr>
<td>IL-22-R1 backward</td>
<td>5’-CGT GCT CCT GGA TGA AGC-3’</td>
<td>2,042</td>
<td>6</td>
</tr>
<tr>
<td>IP10 forward</td>
<td>5’-GAA AGC AGT TAG CAA GGA AAG GT-3’</td>
<td>2,130</td>
<td>28</td>
</tr>
<tr>
<td>IP10 backward</td>
<td>5’-GAC ATA TAC TCC ATG TAG GGA AGT GA-3’</td>
<td>2,104</td>
<td>34</td>
</tr>
</tbody>
</table>

4.1.10. Human cell lines

**Human colorectal cancer cell lines**

Caco-2 kindly provided by Dr. Andreas Herbst, Medizinische Klinik II, Klinikum der Universität München

Colo205 kindly provided by Universitätsklinikum Hamburg Eppendorf, UCCH Hubertus Wald Tumorzentrum

DLD-1 kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum der Universität München

HCT116 kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum der Universität München

HT29 kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum der Universität München

SW480 kindly provided by Dr. Andreas Herbst, Med. Klinik II Klinikum der Universität München

SW620 kindly provided by Prof. Dr. Klaus-Peter Janssen, Department of Surgery, Technische Universität München
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

**Other human cell lines**

Karpas299 kindly provided by Deutsches Krebsforschungszentrum Heidelberg (DKFZ)

### 4.1.11. Equipment

- **Balance (LP 6209)**: Sartorius, Göttingen, Germany
- **Cell culture CO2 incubator (BD 6220)**: Heraeus, Hanau, Germany
- **Cell culture laminar flow**: Heraeus, Hanau, Germany
- **Centrifuge 5417 R**: Eppendorf, Hamburg, Germany
- **Centrifuge 5424**: Eppendorf, Hamburg, Germany
- **FACSCanto II**: Becton Dickinson, San Jose, USA
- **Gel electrophoresis systems**: Bio-rad, Munich, Germany
- **LightCycler 2.0 System**: Roche, Mannheim, Germany
- **Mithras LB940 multilabel plate reader**: Berthold, Bad Wildbad, Germany
- **Multifuge 3L-R**: Heraeus, Hanau, Germany
- **Nanodrop ND-1000**: NanoDrop, Wilmington, USA
- **Neubauer hemocytometer Optik Labor**: FrischknechtBalgach, Germany
- **Omnifuge 2 ORS**: Heraeus, Hanau, Germany
- **pH meter**: WTW, Weilheim, Germany
- **Power Supply 200/2.0**: Biorad, Munich, Germany
- **Refrigerators (4°C, -20°C, -80°C)**: Thermo Scientific, Waltham, USA
- **Shaker**: NeoLab, Heidelberg, Germany
- **Thermocycler T3**: Biometra, Göttingen, Germany
- **Thermomixer**: Eppendorf, Hamburg, Germany
- **Vortex VF2**: Janke & Kunkel, Staufen, Germany
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.1.12. Patient samples

Irreversibly anonymized consecutive tumor samples from patients suffering from cancer of the colon or the rectum were collected by Dr. Jens Neumann, Pathologisches Institut, LMU, Munich. Analysis of anonymised patient tissue samples was performed as approved by the local ethics committee.

Table 7: Tumor and normal tissue samples details

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sample number</th>
<th>Histology</th>
<th>Age at diagnosis</th>
<th>Gender</th>
<th>Localization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C1</td>
<td>Adenocarcinoma</td>
<td>70</td>
<td>Male</td>
<td>Coecum</td>
</tr>
<tr>
<td></td>
<td>C2</td>
<td>Adenocarcinoma</td>
<td>70</td>
<td>Male</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td></td>
<td>N1/2</td>
<td>Normal tissue</td>
<td>70</td>
<td>Male</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td>2</td>
<td>C3</td>
<td>Adenocarcinoma</td>
<td>67</td>
<td>Female</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td></td>
<td>N3</td>
<td>Normal tissue</td>
<td>67</td>
<td>Female</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td>3</td>
<td>C4</td>
<td>Adenocarcinoma</td>
<td>66</td>
<td>Female</td>
<td>Rektum</td>
</tr>
<tr>
<td></td>
<td>N4</td>
<td>Normal tissue</td>
<td>66</td>
<td>Female</td>
<td>Rectum</td>
</tr>
<tr>
<td>4</td>
<td>C5</td>
<td>Adenocarcinoma</td>
<td>66</td>
<td>Male</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td></td>
<td>N5</td>
<td>Normal tissue</td>
<td>66</td>
<td>Male</td>
<td>Colon ascendens</td>
</tr>
<tr>
<td>5</td>
<td>C6</td>
<td>Adenocarcinoma</td>
<td>85</td>
<td>Female</td>
<td>Rectum</td>
</tr>
<tr>
<td></td>
<td>N6</td>
<td>Normal tissue</td>
<td>85</td>
<td>Female</td>
<td>Rectum</td>
</tr>
<tr>
<td>6</td>
<td>C7</td>
<td>Adenocarcinoma</td>
<td>82</td>
<td>Male</td>
<td>Rectum</td>
</tr>
<tr>
<td></td>
<td>N7</td>
<td>Normal tissue</td>
<td>82</td>
<td>Male</td>
<td>Rectum</td>
</tr>
<tr>
<td>7</td>
<td>C8</td>
<td>Adenocarcinoma</td>
<td>59</td>
<td>Male</td>
<td>Sigma</td>
</tr>
<tr>
<td></td>
<td>N8</td>
<td>Normal tissue</td>
<td>59</td>
<td>Male</td>
<td>Sigma</td>
</tr>
</tbody>
</table>
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Table 8: Tumor and normal tissue sample staging of tumor. Abbreviations are: T = tumor, N = nodes, Ln = lymph nodes, M = metastasis, L = lymphatic vessel invasion, V = vein invasion, Pn = perineural invasion, UICC = Union internationale contre le cancer

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sample number</th>
<th>Grading</th>
<th>T</th>
<th>N</th>
<th>Number</th>
<th>M</th>
<th>L</th>
<th>V</th>
<th>Pn</th>
<th>UICC-Stadium</th>
<th>R-Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C1</td>
<td>2 3</td>
<td>1b</td>
<td>3/47</td>
<td></td>
<td>1b (PER)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>IVB</td>
<td>Rx</td>
</tr>
<tr>
<td></td>
<td>C2</td>
<td>2 3</td>
<td>1b</td>
<td>3/47</td>
<td></td>
<td>1b (PER)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>IVB</td>
<td>Rx</td>
</tr>
<tr>
<td></td>
<td>N1/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>C3</td>
<td>3 4b</td>
<td>2b</td>
<td>18/23</td>
<td></td>
<td>1b (PER)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>IVB</td>
<td>Rx</td>
</tr>
<tr>
<td></td>
<td>N3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>C4</td>
<td>2 3</td>
<td>2b</td>
<td>12/42</td>
<td>x</td>
<td></td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>IIIC</td>
<td>R0</td>
</tr>
<tr>
<td></td>
<td>N4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>C5</td>
<td>2 3</td>
<td>1b</td>
<td>2/24</td>
<td>x</td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>III</td>
<td>R0</td>
</tr>
<tr>
<td></td>
<td>N5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>C6</td>
<td>3 3</td>
<td>2a</td>
<td>4/13</td>
<td>1a (HEP)</td>
<td></td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>IVA</td>
<td>R0</td>
</tr>
<tr>
<td></td>
<td>N6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>C7</td>
<td>3 4b</td>
<td>0</td>
<td>0/17</td>
<td>x</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>IIC</td>
<td>R0</td>
</tr>
<tr>
<td></td>
<td>N7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>C8</td>
<td>3 4b</td>
<td>0</td>
<td>0/32</td>
<td>x</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>IIIC</td>
<td>R0</td>
</tr>
<tr>
<td></td>
<td>N8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4.1.13. Computer programs

Adobe Creative Suite  
Adobe Systems, San Jose, USA
BD FACSDiva  
BD Biosciences, San Diego, USA
Endnote X4  
Thompson Reuter, Carlsbad, USA
Flowjo887  
Tree Star, Ashland, USA
GraphPad Prism, Version 5.0b  
GraphPad Software, La Jolla, USA
Microsoft Office  
Microsoft, Redmond, USA
Light Cycler 480 software release  
1.5.0 SP4
4.2. Methods
4.2.1. Molecular biology
4.2.1.1. Isolation of cytoplasmatic RNA

To isolate RNA from human colon cancer cell lines the InviTrap® Spin Cell RNA Mini Kit (Stratec) was used. Purification was done according to the protocol provided by the manufacturer.

4.2.1.2. Reverse transcription

Complete RNA was reversely transcribed in first strand copy-DNA (cDNA) using the RevertAid First Strand cDNA Synthesis Kit. 1 - 2 µg of total RNA was used. For low concentrated samples a maximum of 11 µl of RNA was used. The RNA was mixed with Oligo-(dT)₁₈ primer, 5 x Reaction buffer, RiboLock RNase Inhibitor, dNTP Mix and RevertAid M-Mul reverse transcriptase. cDNA was either directly used or stored at -20°C.

4.2.1.3. Real time quantitative reverse transcription PCR (qRT-PCR)

To quantify mRNA levels qRT-PCR was used. 2 µl of cDNA was mixed with 5 µl of molecular probe master mix, 0.4 µl forward primer, 0.4 µl backward primer, 3 µl H₂O and 0.2 µl molecular probe.

Analysis was performed using a LightCycler 2.0 System (Roche) and quantification using Light Cycler 480 software release 1.5.0 SP4. HPRT was used as reference gene. For stimulations of colorectal cancer cells with cytokines, expression was normalized to unstimulated controls (set to 1).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.2.2. Cell culture methods

4.2.2.1. General conditions

Cell culture was carried out under a laminar flow hood to ensure sterile conditions. The cells were grown in commercially available disposable tissue culture flasks and dishes, and incubated at 37ºC, 5% CO2 - air mixture and 95% atmospheric humidity. Cell numbers and viability were tested by trypan blue staining. Cells were counted using a Neubauer hemocytometer.

4.2.2.2. Culturing medium for human cell lines

<p>| Table 9: | Culturing medium for human cell lines and primary cells |</p>
<table>
<thead>
<tr>
<th>Cell line(s)</th>
<th>Medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caco-2 HCT116 DLD-1 SW480 SW620</td>
<td>DMEM supplemented with 10% heat inactivated fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 mg/ml)</td>
</tr>
<tr>
<td>Colo205 Karpas299</td>
<td>RPMI medium supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 mg/ml)</td>
</tr>
<tr>
<td>HT29</td>
<td>McCoy’s 5A medium supplemented with 10% heat inactivated FCS, 2 mM L-glutamine, penicillin (100 U/l), streptomycin (0.1 mg/ml)</td>
</tr>
</tbody>
</table>

4.2.2.3. Cell stimulations using recombinant cytokines

Colorectal cancer cell lines were stimulated with IL-22 (50 ng/ml), IFN-γ (10 ng/ml) and TNF-α (20 ng/ml) alone or in combination. For stimulation, cells were plated onto 6- or 24-well plates and allowed to adhere overnight. Medium was removed and cells were washed once with PBS. For STAT3 and pSTAT3 stimulation cells were starved 4 h in Opti-MEM prior to stimulation with recombinant IL-22. For proliferation assays, a Neubauer chamber was used for cell quantification.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.2.2.4. Preparation of whole protein lysates from colorectal cancer cell lines

Cells grown in suspension were collected and adherent cells were detached by trypsinization. Cells were washed once with PBS and pellets were resuspended in 1 x lysis buffer supplemented with protease inhibitor cocktail. Cells were kept 30 - 45 min on ice and vortexed shortly every 10 min. Cell debris was removed by centrifugation for 15 min at maximum rpm at 4 °C. Cell lysates were stored at -20 °C.

4.2.3. Immunological methods

4.2.3.1. Bradford assay

Total protein concentration of lysates from colorectal cancer cells was assessed using the Bradford method (Bradford, 1976).

4.2.3.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE)

To separate proteins according to their molecular mass, SDS-PAGE was used. Protein samples were boiled for 5 min at 95 °C in Laemmli buffer (Laemmli, 1970) under reducing conditions (including β-mercaptoethanol). Proteins were separated at a constant voltage of 100 V.

4.2.3.3. Western blot

After SDS Page, proteins were transferred onto a PVDF membrane at 360 Ampere for 60 min. Unspecific binding was blocked with 5% milk powder in TBST for 60 min at room temperature (RT). RT is defined as the temperature that is currently in the laboratory. Membranes were incubated with primary antibody overnight at 4 °C. Secondary antibody was incubated 60 - 120 min at RT. Afterwards the membrane was washed 3 x and Western blotting substrate was applied to the membrane. Chemo luminescence was detected using a CCD camera system (ImageQuant LAS 4000 mini).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

4.2.3.4. Enzyme-linked immunosorbent assay (ELISA)

Cytokine concentrations of culture supernatant were determined by using sandwich ELISA, according to the protocol of the manufacturer.

4.2.3.5. Flow cytometry

All measurements were performed on an analytical FACS Canto II three laser system.

4.2.3.5.1. Analysis of surface molecule expression

Expression of surface molecules was assessed by adding fluorochrome-conjugated monoclonal antibodies.

4.2.3.5.2. Intracellular cytokine staining

Cells were stimulated with PMA (50 ng/ml) and ionomycin (1 µg/ml) in the presence of Golgistop (brefeldin A, 4 µg/ml) for 4 - 5 h at 37 °C of intracellular cytokine expression analysis. Afterwards cells were washed 2 x with PBS and surface antigens were stained. Cells were then fixed using IC Fixation (eBioscience) for 20 min at RT. Cells were washed 1 x with PBS and left over night in PBS at 4 °C. After washing cells twice with 1 x permeabilisation buffer (eBioscience), cells were stained in 100 µl 1 x permeabilisation buffer supplemented with fluorochrome-conjugated monoclonal antibodies against the cytokines of interest for 30 min at 4 °C. Afterwards cells were washed 1 x with 1 x permeabilisation buffer, 1 x with PBS.
4.2.3.5.3. Apoptosis assay: Annexin V and PI staining

Apoptosis assay was performed using Annexin V and propidium iodide (PI) staining. Cells were harvested and transferred to FACS tubes and washed 1 x with PBS. Afterwards 200 µl 1 x Annexin V buffer was added per tube together with Annexin V APC antibody. Shortly before FACS analysis, PI was added.

4.2.3.5.4. Preparation and staining of colorectal cancer tissue

Samples from colorectal cancer patients were collected and stored at 4 °C in complete RPMI until digestion of the sample with 1 mg/ml collagenase and 0.05 mg/ml DNAse I at 37 °C for 30 min under mild shaking. Tissues were then sequentially dissociated by mashing through 100 µm and 40 µm cell strainers to generate single cell suspension. Cells were stimulated as described above. Cells were washed 2 x with PBS and fixable live dead staining was performed in 1 ml PBS for 30 min at 4°C. Cells were fixed and stored overnight at 4 °C after surface staining.

Intracellular staining was performed using IL-22, IL-17A and IFN-γ specific antibodies as well as appropriate isotype controls.

4.3. Statistical analysis

Columns and error bars indicate means and standard errors of the mean (SEM). Differences in experimental data sets were analyzed using unpaired (patient samples) or paired (cell culture experiments) two-sided Student's t-test. p < 0.050 are considered as statistically significant. Number of independent experiments is stated for each figure.
5. Results
5.1. Cellular sources of IL-22 in human tissue
5.1.1. Frequencies of IL-22 producing T cells in human PBMC

To evaluate Th-22 cell function in experiments, the frequency of Th-22 cells was evaluated in PBMC of 8 healthy individuals. Th-22 cells are defined as CD4$^+$ T cells that produce IL-22 in the absence of IL-17 and IFN-γ. The gating strategy is shown in figure 4. We defined Th-22 cells as CD3$^+$ CD4$^+$ CD8$^-$ IL-17$^-$ IL-22$^+$ and IFN-γ$. Th-17 cells were defined as CD3$^+$ CD4$^+$ CD8$^-$ IL-17$^+$ and IFN-γ$, and Th1 cells as CD3$^+$ CD4$^+$ CD8$^-$ and IFN-γ$. Th-22 and Th-17 cells were found at low frequencies, in contrast to Th-1 cells which were the most abundant Th-subpopulation. The frequency range of Th-22 cells was 0.3 – 0.7 %, the range of Th-17 was 0.3 – 0.8 % and the range of Th-1 cells was 3.7 – 10.1 % (see figure 5).

Figure 4: Gating strategy example of one healthy donor. Samples from a total of 8 healthy donors were purified by Biocoll density gradient centrifugation and restimulated with PMA and ionomycin in the presence of brefeldin A. PBMC were stained for surface CD3, CD4 and CD8 as well as for intracellular IL-22, IL-17A and IFN-γ. Results are shown for one representative donor. CD3$^+$ CD4$^+$ CD8$^-$ T cells were analyzed for their IL-22 and IL-17A production. Numbers indicate relative percentages per quadrant.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Figure 5: Frequencies of IL-22-producing T cells in PBMC of healthy donors. Samples from a total of 8 healthy donors were purified by Biocoll density gradient centrifugation and restimulated with PMA and Ionomycin in the presence of brefeldin A. PBMC were stained for CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ. Frequencies of Th-22 (CD3+ CD4+ CD8− IL-22+ IL-17A− IFN-γ−), Th-17 (CD3+ CD4+ CD8− IL-17A+ IFN-γ−), and Th-1 (CD3+ CD4+ CD8− IFN-γ+) cells within the CD3+ cell population. Mean with SEM is indicated.

While CD4+ T cells are the main producers of IL-22, low frequencies of IL-22+ CD8+ T cells were also detected (see figure 6).

Figure 6: CD8+ IL-22 producing T cells in PBMC from healthy donors. PBMC of a total of 8 healthy donors were purified by Biocoll density gradient centrifugation and restimulated with PMA and Ionomycin in the presence of brefeldin A. CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ was performed. (A) One representative donor is shown as FACS blot gated from CD3+ CD8+ T cells. (B) Frequencies of IL-22+ cells within CD3+ CD8+ T cells of 8 donors. Mean with SEM is indicated.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

5.1.2. T-helper cell subpopulations producing IL-22 are found in the tumor tissue of colorectal cancer patients

To further dissect the role of IL-22 in tumor biology, we applied the above described technique to analyze IL-22-producing cells in primary colorectal cancer tissue. For each patient a tissue sample from the tumor and a sample from neighboring tissue macroscopically not affected by the tumor (herein referred to as ‘normal tissue’) were collected.

Samples from patients with colorectal cancer were analyzed for CD3, CD4 and CD8 surface expression and IL-22, IL-17 and IFN-γ intracellular cytokine staining.

Figure 7 shows the numbers of Th-1, Th-17 and Th-22 as proportions of CD3+ T cells Numbers of Th-17 and Th-22 were low compared to Th-1 cells. For Th-17 and Th-1 cells there is a trend towards higher numbers in tumor tissue. However, the frequencies of Th-1, Th-17 and Th-22 cells are not significantly different in tumor compared to normal tissue.

![Figure 7: Frequencies of Th-22, Th-17 and Th-1 in samples from colorectal cancer patients.](image)

CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ were performed. Frequencies of Th-22 (CD3+ CD4+ CD8- IL-22+ IL-17A+ IFN-γ), Th-17 (CD3+ CD4+ CD8- IL-17+ IFN-γ), and Th-1 (CD3+ CD4+ CD8- IFN-γ) cells within the CD3+ CD4+ CD8- cell population of tumor and normal tissue from 7 patients are shown, for one patient with dual carcinoma two specimens were taken. Mean with SEM is indicated.

A population of IL-22+ T cells that was IFN-γ+ (CD3+CD8-CD4+IL-17+IL-22+) T cells was found in higher numbers in normal tissues compared to tumor tissue (p=0.046) (figure 8A).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Figure 8: Frequencies of tumor infiltrating lymphocytes. Lymphocytes were isolated from colorectal cancer biopsies and restimulated with PMA and ionomycin in the presence of brefeldin A. Afterwards CD3, CD4 and CD8 surface staining as well as intracellular staining for IL-22, IL-17A and IFN-γ was performed. (A) Frequencies of CD3⁺CD8⁻CD4⁺IL-17⁻IL-22⁺ within CD4⁺ T cells. (B) CD8⁺ IL-22 producing T cells are found in normal and colorectal cancer tissue. Results of normal and cancer tissue from 7 patients are shown, for one patient with dual carcinoma two specimens were taken. Mean with SEM is indicated.

Using flow cytometry, we found a proportion of the CD8⁺ T cells to stain positive for IL-22. Equal amounts of IL-22 producing CD8⁺ T cells were found in normal and tumor tissue (p=0.252) (figure 8B).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

5.2. **Effect of IL-22 on human colorectal cancer cell lines**

To understand the effect of IL-22 production at the tumor site, we next performed *in vitro* assays using a panel of human colorectal cancer cell lines (n = 6).

5.2.1. **Colorectal cancer cell lines do not produce IL-22**

To test if colorectal cancer cell lines have the ability to produce IL-22, we tested Colo205, CaCo2, DLD-1, HCT116, HT29 and SW480 for IL-22 secretion by ELISA and IL-22 expression by qRT-PCR. The tested cell lines do not secrete IL-22 and no significant mRNA levels were found for the IL-22 transcript, indicating that these colorectal cancer cell lines do not produce IL-22 (figure 9).

![Figure 9](image)

**Figure 9: Colorectal cancer cell lines do not produce IL-22.** (A) Analysis of IL-22 mRNA in colorectal cancer cell lines by qRT-PCR. For qRT-PCR data relative expression of IL-22 to hypoxanthin-phosphoryboslavyltransferase (HPRT) for each cell line was calculated by the Light Cycler relative quantification software. The human lymphoma cell line Karpas 299 served as positive control. (B) Supernatants of colorectal cancer cell lines were tested for IL-22 content by ELISA. The cell line Karpas 299 served as positive control. The error bars represent standard error of the mean of duplicates. Results are representative for at least two independent experiments.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

5.2.2. Colorectal cancer cells express IL-22-R1

To further dissect the potential role of IL-22 in colorectal cancer, we next studied expression of IL-22-R1 on colorectal cancer cell lines. IL-22-R1 expression was assessed by Western blot analysis and qRT-PCR. IL-22-R1 was found in all cell lines analyzed on mRNA and on protein level (figure 10).

![Figure 10](image)

**Figure 10:** Colorectal cancer cell lines express IL-22-R1 on mRNA and protein level. (A) Analysis of IL-22-R1 mRNA in colorectal cancer cell lines by qRT-PCR. For qRT-PCR data relative expression of IL-22-R1 to HPRT for each cell line was calculated by the Light Cycler relative quantification software. (B) 40 µg protein of whole cell lysate was loaded per lane. IL-22-R1 expression was detected by Western blot. β-actin served as loading control. One representative of at least two is shown.

5.2.3. IL-22 signaling pathway is functional in colorectal cancer cells

In cancer cells, STAT3 is the major signal transducing molecule upon IL-22 stimulation. To test ability of the six colorectal cancer cell lines to respond to IL-22 stimulation, cells were treated with 100 ng/ml IL-22 for 10, 30 and 60 min and analyzed for STAT3 phosphorylation by Western blot.

All tested colorectal cancer cell lines (Colo205, CaCo2, DLD-1, HCT116, HT29 and SW480) responded to IL-22 stimulation by STAT3 phosphorylation. Phosphorylation of STAT3 is shown exemplarily in figure 11 for the cell lines HT29 and Colo205.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

5.2.4. IL-22 stimulation induces release of IL-10 and VEGF from Colo205 cells

To further dissect the downstream effects of IL-22 stimulation, we analyzed the secretion of IL-10 and VEGF, which are both induced by pSTAT3 activation. Upon IL-22 stimulation, IL-10 secretion was induced (figure 12A) and VEGF secretion was enhanced in a time dependent manner (figure 12B).
Figure 12: IL-22 induces IL-10 secretion from Colo205 cells. Colo205 cells were seeded in 96 well plates and stimulated with 50, 100 or 200 ng/ml IL-22. Supernatants were collected at 6, 24 and 48 h and the (A) IL-10 content and (B) VEGF concentration was measured by ELISA. One representative experiment of three independent experiments is shown. Error bars represent SEM of duplicates.
5.2.5. IL-22 induces proliferation of Colo205 cells

Another consequence of STAT3 phosphorylation in cancer cells is cell proliferation. To analyze if IL-22 stimulation would induce proliferation of colorectal cancer cells, we stimulated Colo205 cells with different concentrations of IL-22 (see figure 13). Shown are fold change normalized to unstimulated controls after 48 hours. IL-22 stimulation dose-dependently induced proliferation of Colo205 cells (figure 15, p = 0.023) for the 100 ng/ml condition versus unstimulated).

![Figure 13: Colo205 cells proliferate upon IL-22 stimulation in a concentration dependent manner.](image)

5.3. Effect of IL-22 on IFN-γ-induced CCL22 production of tumor cells

5.3.1. IL-22 inhibits IFN-γ-induced CCL22 secretion in HT29 cells

Because IL-22 may interact with the downstream effects of IFN-γ, we sought to further investigate the effect on other IFN-γ-mediated effects such as chemokine secretion (Berin et al, 2001; Kaplan et al, 1987; Pennino et al, 2013). The colorectal cancer cell line HT29 produces CCL22 after IFN-γ stimulation (Berin et al, 2001).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

HT29 cells were either stimulated with IFN-γ, IL-22 or the combination of both. CCL22 induction was analyzed by qRT-PCR and ELISA. IFN-γ stimulation induced CCL22 (see figure 14A). Addition of IL-22 significantly reduced IFN-γ-induced CCL22 secretion (p = 0.002). However, for IP10 and CCL20 no significances were calculated since the sample number was too low (figure 14B und 14C).

Figure 14: IL-22 downregulates IFN-γ-induced CCL22 in HT29 cells. HT29 cells were treated with IFN-γ (10 ng/ml) or IL-22 (50 ng/ml) for two days in Opti-MEM. Cells were harvested and RNA was extracted. mRNA expression was determined by qRT-PCR for CCL22, IP10 and CCL20. For qRT-PCR data relative expression of IL-22-R1 to HPRT for each cell line was calculated by the Light Cycler relative quantification software and the mean of untreated control HT29 cells was set to 1. (A) Relative expression of CCL22 in HT29 cells is shown. Error bars represent mean with SEM of seven independent experiments. (B) Relative expression of IP10 in HT29 cells is shown. Error bars represent mean with SEM of two independent experiments. (C) Relative expression of CCL20 expression in HT29 cells. Error bars represent mean with SEM of two independent experiments.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

To exclude that the IL-22 effect on IFN-γ –induced CCL22 production was due to apoptosis induction, Annexin V and PI staining on HT29 cells after stimulation was performed. The combination of IL-22 and IFN-γ did not significantly increase the number of Annexin V and PI positive cells (p=0.265) (figure 15).

![Figure 15: Apoptosis and Death of HT29 cells stimulated 2 days in Opti-MEM supplemented with IFN-γ, IL-22 or both. Data are representative for at least two independent experiments. Error bars represent mean with SEM of triplicates. Paired t-test, p<0.05 represents significant difference.](image)

5.3.1.1. IFN-γ upregulates IL-22-R1 on colorectal cancer cells

Because IFN-γ has been described to upregulate IL-22-R1 on keratinocytes (Kunz et al, 2006), we next asked whether this effect could also be observed in colorectal cancer cell lines. HT29 and Colo205 cells were stimulated with IFN-γ or IL-22 and IL-22-R1 expression was analyzed by RT-PCR. IL-22 did not significantly enhance IL-22-R1 expression in HT29 (p=0.067) (figure 16A) and in Colo205 (0.139) cells (figure 16B). IFN-γ enhanced IL-22-R1 expression significantly in HT29 cells (p=0.001). However the induction of IL-22-R1 was not significant in Colo205 cells (p=0.091).
Figure 16: IFN-γ upregulates IL-22-R1 expression in HT29 and Colo205 cells. HT29 (A) and Colo205 (B) cells were treated with IFN-γ (10 ng/ml) or IL-22 (50 ng/ml) for two days. Cells were harvested and cDNA was prepared. mRNA expression was determined by qRT-PCR for IL-22-R1. The mRNA expression of each condition was normalized to expression of HPRT mRNA and the mean of untreated control HT29 and Colo205 cells was set to 1.0, respectively. Error bars represent mean with SEM of four (HT29 cells) and three (Colo205) independent experiments. Paired t-test, p<0.05 represents significant difference.
5.3.1.2. **IL-22 and TNF-α synergistically induce CCL22 in HT29 cells**

HT29 and Colo205 cells were stimulated with IL-22, TNF-α or the combination of both. TNF-α induced CCL22 expression in HT29 cells. Addition of IL-22 to TNF-α significantly increased CCL22 expression in HT29 cells (p = 0.021) (figure 17).

![Figure 17: IL-22 synergizes with TNF-α to induce CCL22 expression in HT29 cells.](image)

Figure 17: IL-22 synergizes with TNF-α to induce CCL22 expression in HT29 cells. HT29 cells were treated with TNF-α (20 ng/ml) or IL-22 (50 ng/ml) for two days in Opti-MEM. Cells were harvested and mRNA and subsequent cDNA was prepared. mRNA expression was determined by real-time PCR for CCL22. The mRNA expression of each condition was normalized to expression of HPRT mRNA and the mean of untreated control HT29 cells was set to one. CCL22 expression in HT29 cells is shown. Error bars represent mean with SEM of five independent experiments.

5.3.1.3. **TNF-α induced upregulation of IL-22-R1 expression in HT29 cells**

To further understand the interaction of IL-22 and TNF-α on colorectal cancer cells, we next investigated the impact of TNF-α on IL-22-R1 expression. IL-22 did not significantly upregulate IL-22-R1. TNF-α and the combination with IL-22 both upregulated IL-22-R1 expression in HT29 cells significantly, p=0.018 and p=0.036, respectively (see figure 18). The combination of TNF-α with IL-22 showed a trend towards further enhancement of IL-22-R1 expression.
Figure 18: TNF-α upregulates IL-22-R1 in HT29 cells. HT29 cells were treated with IL-22 (50 ng/ml) or TNF-α (20ng/ml) alone or in combination for two days in Opti-MEM. Cells were harvested and cDNA was prepared. mRNA expression was determined by real-time PCR for IL-22-R1. The mRNA expression of each condition was normalized to expression of HPRT mRNA and the mean of untreated control HT29 and Colo205 cells was set to one. Error bars represent Mean ± SEM of four independent experiments.
6. Discussion

The present work shows that human PBMC from healthy donors as well as colorectal cancer tissue contain subclasses of IL-22 producing T cells, including Th-1, Th-17 and Th-22 cells as detected by flow cytometry. Low frequencies of CD8+ IL-22 secreting T cells were also detected.

Colorectal cancer cell lines did express IL-22-R1 but not IL-22. IL-22 stimulation induced STAT3 phosphorylation in all tested cell lines. In Colo205 cells IL-22 led to VEGF and IL-10 release as well as cell proliferation. We also showed that IL-22 suppresses IFN-γ-induced CCL22 protein expression in HT29 cells. In addition, IL-22 enhanced TNF-α-induced expression of CCL22 in the same cell line. Both IFN-γ and TNF-α upregulated expression of IL-22-R1.

6.1. IL-22 expression in human PBMC from healthy donors

Our study shows that IL-22 producing T cells can be detected in PBMC. Different Th cell subtypes are present within circulating healthy PBMC (Lu et al, 2015; Luan et al, 2015; Oliveira et al, 2015).

In this thesis, it was shown that Th-1, Th-17 and Th-22 are present in the peripheral blood of healthy donors, consistent with the literature. The focus of the thesis was Th-22 cells that represent a novel T cell subpopulation. The frequency of Th-22 cells was low. Studies by other groups have identified Th-22 cells as a very rare population within PBMC from healthy human donors (Liu et al, 2012; Zhang et al, 2012a). One study detected a mean of 0.8 % circulating Th-22 cells with a range of 0.3 % to 2.1% for Th-17 cells a mean of 1.9 % was found (range, 0.4 % to 4.3 %) (Lu et al, 2015). Another study described low frequencies with up to approximately 0.1 % CD3+ CD4+ IL-22+ cells (Oliveira et al, 2015). An additional study showed for Th-22 cells a median of 0.2 % and a range of 0.5 %, for Th-17 cells a median of 0.4 % and a range of 1.5 % and for Th-1 cells a median of 1.4 % and a range of 15.5 % (Luan et al, 2015). The levels we found for Th-22 cells were 0.3 to 0.7 % and 0.3 to 0.8 % for Th-17 cells. For Th-1 cells we found levels between 3.7 % and 10.1 %.
Th frequencies of Th-22 cells detected in the present thesis are compatible with the low frequencies described in literature. Minor differences may result from different cohorts of donors as well as from methodological differences. Th-22 cells are found in low frequencies in peripheral blood, however they are abundant in tissue. One explanation could be the expression of their characteristic chemokine receptors CCR4 and CCR10. Chemokines binding these receptors are for instance strongly expressed in the skin (Eyerich & Eyerich, 2015).

IL-22 does not act on immune cells but on cells of epithelial origin and therefore represents novel kind of immune modulator within the IL-10 family of cytokines (Wolk et al, 2010). The main functions of IL-22, in healthy individuals, are increase of innate immunity, protection of tissue from damage and enhancement of tissue regeneration.

Particular Th-22 cells have been described to protect epithelial barriers in organs and also modulate injured and inflamed tissue (Eyerich & Eyerich, 2015). IL-22 also plays a role in the defense against bacterial infections (Siegemund et al, 2009) inducing, for instance, antimicrobial molecules (Siegemund et al, 2009; Wolk et al, 2004).

6.2. Expression of IL-22 in colorectal cancer tissue

A Th-22 staining protocol was established and applied to tumor samples from colorectal cancer patients. The presence of IL-22 and/or of Th-22 cells has previously been demonstrated within tumor tissues from patients with colorectal, gastric, hepatocellular, small-and large-cell lung carcinoma (Jiang et al, 2013; Kobold et al, 2013; Liu et al, 2012; Qin et al, 2014).

We detected IL-22 producing Th-1, Th-17 and Th-22 within tumor samples of colorectal cancer patients. These findings are in line with published data as all three T cell types have been described in solid tumors.

CD4⁺ T cells were shown to exert a role in both the induction and the effector phases of the antitumor response (Protti et al, 2014). It has been described that activated CD4⁺ T cells modulate antitumor immune response. Th-1 cells support cytotoxic T cells and
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

secrete cytokines such as IL-2 or IFN-γ and that promote an antitumor response and tissue destruction (Disis, 2010; Pernot et al, 2014).

Th-17 cells are known to be present in the tumor environment of colorectal cancer patients. Tumor-infiltrating IL-17 producing CD4⁺ T cells and macrophages have been associated with poor prognosis for colorectal cancer patients (Fridman et al, 2011; Fridman et al, 2012; Liu et al, 2011a).

Th-22 cells were the focus of this thesis; their involvement in tumor development and role in sustaining established tumors was investigated. We detected low frequencies of Th-22 in both tumor tissue and non-affected tissue. However, it has been shown that Th-22 cell accumulation may be connected to colorectal cancer development, according to published evidence. The authors found increased levels of Th-22 in tumor tissue compared to peritumoral tissue (Huang et al, 2015). In this thesis up to 0.9 % of Th-22 cells as subset of CD4⁺ T cells were found whereas Huang et al., found up to 1.5 % Th-22 cells. The cited publication analyzed a cohort of 18 patients for their Th-22 content via FACS as opposed to the seven patients analyzed here. Thus, discrepancies may be explained by the low power of either study. A larger cohort might be more suitable for comparison of Th-22 in tumor tissue and peritumoral tissue. Peritumoral tissue was used in this thesis as control. However, while the cancer cells do not directly affect this tissue, it is extracted from the same patient suffering from cancer. The T cell repertoire might also be affected by changes resulting either from neighboring cancer cells or by the factors leading to cancer development in the first place. Therefore, the peritumoral tissue may not be strictly considered a healthy tissue and may not have identical characteristics to tissue from a true healthy individual.

Circulating Th-22 are increased in patients with gastric cancer compared to healthy donors and are associated with tumor progression (Liu et al, 2012). Another study demonstrated increased intratumoral CD4⁺IL-22⁺ T cells. The authors correlated Th-22 to tumor progression and lower patient survival (Zhuang et al, 2012). Circulating Th-22 cells are also associated with hepatocellular carcinoma development and disease progression (Qin et al, 2014). For pancreatic cancer patients, intratumoral IL-22 levels and frequencies of CD4⁺ IL-22 producing cells are as well linked to disease progression (Xu et al, 2014).
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

In summary, available data suggests a disease-promoting role of Th-22 in several cancer entities.

In contrast, the function of IL-22 may vary according to the stage of the disease where IL-22 is expressed. For example, transgenic mice that are characterized by constant overproduction of IL-22 in the liver do not spontaneously develop liver tumors (Park et al, 2011). However, IL-22 may support the progression of already developed tumors, as IL-22 induces proliferation in a number of tumor cells from various origins (Kobold et al, 2013).

6.3. Expression of IL-22-R1 and activation of STAT3

To address the question of the effect of IL-22 on colorectal cancer, colorectal cancer cell lines were used as an in vitro model.

To verify that colorectal cancer cells themselves do not produce IL-22, six cell lines were tested for their IL-22 expression. It is widely accepted that IL-22 is not produced by epithelial cells (Wolk et al, 2010). Consistent with this statement, we found no IL-22 expression on protein level in Colo205, HT29, SW480, DLD-1, HCT-116 and Caco-2 cells. The findings of this thesis strengthen the hypothesis that IL-22 found in tumor tissues is expressed by infiltrating immune cells and not by the tumor cells.

To test the responsiveness of these cell lines, IL-22-R1 receptor expression was analyzed. The IL-10-R2 chain of the functional IL-22 receptor complex is ubiquitously expressed and is not limiting in defining IL-22-responsive cells (Wolk et al, 2004). Thus, cellular responsiveness to IL-22 is determined by the expression of IL-22-R1. All tested colorectal cancer cell lines did express IL-22-R1 on protein level. The lymphoma cell lines Karpas299 served as positive control as this cell lines has been described to express IL-22-R1 (Bard et al, 2008).

The findings of this thesis corroborate previously published findings on colorectal cancer cell lines and IL-22-R1 expression (Brand et al, 2006; Di Lullo et al, 2015; Nagalakshmi et al, 2004; Ziesche et al, 2007). However, it cannot be concluded that any cancer cell
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

from any origin necessarily expresses IL-22-R1: one study showed that not all tested multiple myeloma cell lines did express IL-22-R1. They found IL-22-R1 mRNA in approximately one third of the tested cell lines (Di Lullo et al, 2015).

All tested colorectal cancer cell lines showed induction of STAT3 phosphorylation upon IL-22 stimulation, as previously published (Brand et al, 2006; Cella et al, 2009; De Simone et al, 2014; Nagalakshmi et al, 2004). However, IL-22 can also activate other STAT members namely 1 and 5. For all three STATs the major MAPK pathway is activated, leading to phosphorylation of ERK1/2, JNK, and p38 kinase after interaction with the IL-22-R1/IL-10-R2 receptor complex (Lejeune et al, 2002). In cancer cells, most of the downstream effects of IL-22 are thought to be mediated by activation of STAT3 (Boniface et al, 2005; Nagalakshmi et al, 2004; Xie et al, 2000). STAT3 activation has been shown in multiple carcinoma cell lines other than colorectal cancer, such as: in human lung carcinoma cell lines (Kobold et al, 2013), gastric carcinoma cell lines (Fukui et al, 2014), skin basal-cell carcinoma and squamous-cell carcinoma cell lines (Nardinocchi et al, 2015). Since we focused on STAT3 activation for these reasons, we cannot rule out a contribution to IL-22 signaling by other downstream effector molecules.

6.3.1. IL-22 induces VEGF, IL-10 and proliferation in Colo205 cells

We could show that Colo205 secrete IL-10 upon IL-22 stimulation as previously published (Nagalakshmi et al, 2004). Production of IL-10 by Colo205 cells could be a mechanism by which tumor cells suppress inflammatory immune responses, since IL-10 is a crucial anti-inflammatory cytokine (Fiorentino et al, 1991).

On the other hand, we showed that Colo205 cells increased VEGF production upon IL-22 stimulation, as previously demonstrated in HPAFII human pancreatic cancer cells (Curd et al, 2012). A finding which is further corroborated by IL-22+ tumor-infiltrating lymphocytes of colorectal cancer patients increasing VEGF expression in mice with colorectal cancer xenografts (Jiang et al, 2013).

VEGF directly acts on endothelial cells and is the major angiogenic growth factor for cancers and may thus represent a mechanism by which IL-22 could help colorectal
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

cancer progression (Carmeliet & Jain, 2000; Pepper et al, 1992). However, none of the other tested colorectal cancer cell lines did produce IL-10 or VEGF after IL-22 stimulation, which may indicate a cell line specific over a disease specific effect of IL-22.

A number of studies demonstrated proliferation of tumor cells in response to IL-22 (Brand et al, 2006; Di Lullo et al, 2015; Kobold et al, 2013; Nardinocchi et al, 2015) which is further supported by our results of increased proliferation of Colo205 cells upon IL-22 stimulation. Supernatants derived from NK-22, which produce IL-22, stimulate Colo205 cells to proliferate, which is in line with our data (Cella et al, 2009).

In summary, these findings support the idea that IL-22 may contribute to enhanced tumor growth, progression and angiogenesis by cytokine, growth factor and proliferation induction.

6.4. Crosstalk of IL-22 pathway with signaling of IFN-γ and TNF-α

Multiple cytokines are involved in tumor formation and growth. However, their pro- or antitumor role depend on the balance of the different cytokines as well as on the stage of the cancer (Landskron et al, 2014). IL-22 can act pro- and anti-inflammatory on tissue homeostasis. On the one hand, IL-22 promotes epithelial cell regeneration and protects tissues from damage while playing a crucial inflammatory role in a pathological context (Nikoopour et al, 2015). The reasons for the dual role of IL-22 in intestinal homeostasis are not elucidated but might be related to microbial stimulation and that maintained production in response to chronic bacterial stimulation eventually promotes disease (Kirchberger et al, 2013). These paradox functions may be explained by the presence or absence of other cytokines.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

6.4.1. IL-22 inhibits IFN-γ-induced CCL22 secretion in HT29 cells

IFN-γ is one of the Th1 prototypical cytokines and often co-secreted with IL-22. However the possible interplay of IL-22 and IFN-γ has not been systematically investigated.

IFN-γ can lead to the upregulation of MHC-I, MHC-II and ICAM-1 in epithelial cells thus enhancing adhesion of CD4^+ and CD8^+ T cells and apoptosis induction in epithelial cells affected (Miyahara et al, 2004; Pennino et al, 2010; Schwarze et al, 1999; Traidl et al, 2000). IL-22 can antagonize IFN-γ-induced MHCI, MHCII and CD54-intercellular adhesion molecule upregulation in bronchial epithelial cells indicating a regulatory function of IL-22 in the context of IFN-γ-induced inflammation (Pennino et al, 2013). These findings led us to hypothesize that IL-22 may also affect the regulation of other proteins such as chemokines.

IFN-γ induces chemokines in epithelial cells such as colorectal cancer cells. In the intestinal mucosa, intestinal epithelial cells are an important source of chemokines. The observed CCL22 upregulation in HT29 upon IFN-γ stimulation is consistent with published data (Berin et al, 2001).

In the intestinal mucosa, multiple immune cells are capable of producing IFN-γ: B and T lymphocytes, mononuclear phagocytes, and dendritic cells, as well as smaller numbers of eosinophils and mast cells (Berin et al, 2001). We hypothesized that IL-22 might play a role in the tumor microenvironment by regulating chemokine expression in tumor cells. In our experiments, IL-22 did impair IFN-γ-induced chemokine release for CCL22 in HT29 cells.

Our findings suggest that IL-22 can inhibit some effects of IFN-γ. Induction of CCL22 in the tumor microenvironment can lead to the attraction of CCR4-positive immune cells such as Th-17 cells, Th-22 and Tregs. Further, Th-17 cells are attracted by CCL22 and their signature cytokine IL-17 exerts an inflammatory and protumorigenic role (He et al, 2012; Hyun et al, 2012). Th-22 cells also express CCR4 and produce mainly IL-22 (Duhen et al, 2009) and IL-22 can exert a protumorigenic role itself. The inhibition of CCL22 expression by IL-22 in this case would lead to less attraction of these cells and thus to an antitumor response.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

However, Tregs play a crucial role during the control of antitumor immune responses. Tregs can produce immunosuppressive cytokines such as IL-10, TGF-β and IL-35 (Nishikawa & Sakaguchi, 2010). Thus by inhibiting CCL22 secretion, IL-22 may reduce the attraction of immunosuppressive Tregs and thus exert a protumorigenic function.

IFN-γ upregulated IL-22-R1 in HT29 cells. This finding is supported by a study where keratinocytes upregulated IL-22-R1 upon IFN-γ (Kunz et al, 2006).

6.4.1.1. IL-22 and TNF-α synergistically induce CCL22 and in HT29 cells

We next investigated whether IL-22 can interfere with the TNF-α pathway in colorectal cancer cells. This is of particular importance, as these two cytokines are co-secreted by Th-22 cells (Eyerich et al, 2009).

TNF-α is a cytokine with well-described anti-cancer effects and has been used in anti-cancer therapy for patients suffering from solid tumors (Bertazza & Mocellin, 2010). However, in the recent years a dual role of TNF-α has been described, as this cytokine is also capable of driving tumor elimination (Lebrec et al, 2015). In colorectal cancer it has been reported that TNF-α might play a tumor-promoting role (Grivennikov & Karin, 2011).

For HT29 cells, TNF-α highly upregulates CCL22 (Berin et al, 2001) which is consistent with our data, showing upregulation of CCL22 by TNF-α on mRNA level. Addition of IL-22 to TNF-α on tumors cells led to a functional synergism of TNF-α and IL-22: the combination lead to upregulation of CCL22 in HT29 cells. As mentioned above, CCL22 is a chemokine that is a chemoattractant for Tregs and may thus anti-cancer immune responses.

So far, few studies investigated the functional interplay of IL-22 and TNF-α. Eyerich et al., could demonstrate that TNF-α and IL-22 synergistically induce an innate immune profile in human keratinocytes including IP10, CXCL12 and HBD-2 (Eyerich et al, 2011). This synergism is mediated by the MAP kinase p38.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

IL-22-R1 in both keratinocytes and dermal fibroblasts is induced by TNF-α (Wolk et al, 2009; Wolk et al, 2004). These data strengthen our finding that TNF-α upregulates IL-22-R1 in HT29 cells. By upregulating IL-22-R1 on tumor cells, these cells become more sensitive to IL-22 and thus the synergistic effect of TNF-α and IL-22 might be enhanced.

6.5. Conclusion and perspectives

Since IL-22 plays a crucial role in inflammation and proliferation, it might have promise as a potential therapeutic for different cancer entities including colorectal cancer. Our data that IL-22 has an impact on colorectal cancer cells promotes the idea that IL-22-targeting may be a reasonable strategy for cancer therapy. As IL-22 does not act on immune cells itself, modulation of the IL-22/IL-22-R1 axis may have a different safety profile than the targeting of other cytokine pathways which than have profound immune suppressive effects.

Neutralizing antibodies could target IL-22. IL-22 neutralizing antibodies are being tested in autoimmune disorders such as psoriasis and RA (https://clinicaltrials.gov/ct2/show/NCT01941537). On the other hand, blockade of chemokines that attract IL-22 producing T cells such as CCL20 may diminish the impact of IL-22 on the tumor milieu.

Since the data presented here only touches on the biology of IL-22 further studies will be needed to better understand the role of IL-22 in cancer genesis and progression.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

7. References


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

J Clin Invest 119: 3573-3585

Eur J Immunol 41: 1894-1901

J Immunol 146: 3444-3451

Cancer Res 71: 5601-5605

Nat Rev Cancer 12: 298-306

Br J Cancer 111: 763-771

Arthritis Rheum 60: 390-395

Transl Oncol 4: 9-19

Cell Immunol 254: 81-84

Cancer Cell 15: 103-113
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

*J Exp Med* 166: 1098-1108


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

**J Exp Med** 203: 2271-2279


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009). Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. *Nat Immunol* 10: 864-871
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

*J Immunol* 188: 462-469

Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B (2009). Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. 

*Hepatology* 59: 1207


*Cytokine Growth Factor Rev* 21: 365-379

*J Mol Med (Berl)* 87: 523-536

Wolk K, Kunz S, Asadullah K, Sabat R (2002). Cutting edge: immune cells as sources and targets of the IL-10 family members? 
*J Immunol* 168: 5397-5402

*Immunity* 21: 241-254

*J Immunol* 178: 5973-5981

*Eur J Immunol* 36: 1309-1323

Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

_Semin Immunopathol_ 32: 17-31

_J Mol Biol_ 382: 1168-1183

_Clin Immunol_ 147: 38-39

Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney AL (2000). Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R.
_J Biol Chem_ 275: 31335-31339

_Pancreas_ 43: 470-477

_Cancer Lett_ 326: 23-32

_Immunity_ 29: 947-957

_PLoS One_ 6: e20382

_J Clin Immunol_ 31: 606-614

Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, Hu NW, Ma DX, Li ZF, Yang Q, Li W, Li JM (2012a). Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.
_PLoS One_ 7: e31000

_Clin Cancer Res_ 14: 6432-6439
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

8. Appendices

8.1. Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHR</td>
<td>Aryl hydrocarbon receptor</td>
</tr>
<tr>
<td>APC</td>
<td>Allophycocyanin</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CCR</td>
<td>Chemokine receptor</td>
</tr>
<tr>
<td>CCL</td>
<td>Chemokine ligand</td>
</tr>
<tr>
<td>CD</td>
<td>Custer of differentiation</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary deoxyribonucleic acid</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene diamine tetraacetic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence-activated cell sorting</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>HPRT</td>
<td>Hypoxanthine phosphoribosyltransferase</td>
</tr>
<tr>
<td>HRP</td>
<td>Horseradish peroxidase</td>
</tr>
<tr>
<td>h</td>
<td>Hours</td>
</tr>
<tr>
<td>IFN</td>
<td>Interferon</td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IL-22BP</td>
<td>IL-22 binding protein</td>
</tr>
<tr>
<td>IL-10-R2</td>
<td>IL-10 receptor-2</td>
</tr>
<tr>
<td>IL-22-R1</td>
<td>IL-22 receptor-1</td>
</tr>
<tr>
<td>IBD</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>JAK</td>
<td>Janus kinase</td>
</tr>
<tr>
<td>LTI</td>
<td>Lymphoid tissue inducer</td>
</tr>
<tr>
<td>LTI-like</td>
<td>Lymphoid tissue-like inducer</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger ribonucleic acid</td>
</tr>
</tbody>
</table>
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NK cells</td>
<td>Natural killer cells</td>
</tr>
<tr>
<td>NKT cell</td>
<td>Natural killer T cell</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>PBMC</td>
<td>Peripheral blood mononuclear cells</td>
</tr>
<tr>
<td>pDC</td>
<td>Plasmacytoid dendritic cell</td>
</tr>
<tr>
<td>PE</td>
<td>Phycoerythrin</td>
</tr>
<tr>
<td>PerCP</td>
<td>Peridinin chlorophyll protein</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium iodide</td>
</tr>
<tr>
<td>PVDF</td>
<td>Polyvinylidene fluoride</td>
</tr>
<tr>
<td>qRT-PCR</td>
<td>Quantitative reverse transcription polymerase chain reaction</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RORγt</td>
<td>Retinoic-acid-related orphan nuclear receptor</td>
</tr>
<tr>
<td>RPMI</td>
<td>Roswell Park Memorial Institute</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse transcription polymerase chain reaction</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SH2</td>
<td>Sarcoma homology 2</td>
</tr>
<tr>
<td>STAT</td>
<td>Signal transducer and activator of transcription</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming growth factor-β</td>
</tr>
<tr>
<td>Th</td>
<td>T helper</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>TYK2</td>
<td>Tyrosine kinase 2</td>
</tr>
</tbody>
</table>
8.2. Publications

Work performed during my doctoral thesis:


Work performed prior to doctoral thesis:


Abstracts


Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Oral presentations

2. Küpper NJ. Rolle und zelluläre Quellen von Interleukin-22 in Tumorerkrankungen. SYMPOSIUM GENTIANUM, Fünfzehnte Klausurtagung der Medizinischen Klinik und Poliklinik IV Klinikum der Universität München, Frauenchiemsee, Germany, 2013

3. Küpper NJ. Impact of IL-22 on colon cancer. 8th Annual Retreat, Graduiertenkolleg 1202 Oligonucleotides in cell biology and therapy, Ohlstadt, Germany, 2013
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

8.3. Acknowledgements

First I would like to thank my Doktorvater Professor Dr. med. Stefan Endres for his commitment and support during the time of my doctoral thesis. Thank you, Stefan, your enthusiasm and support for the Klin-Pharm are beyond all description.

PD Dr. med. Sebastian Kobold I would like to thank for his patience and support as well as for the supervision of my thesis. His input, professional experience and leadership of our group were always a great help.

Conny Voigt and Vicky Blumenberg, you were the best colleagues I could have imagined for personal and scientific discussions.

Special thanks to the people of Room 2 (Dr. Friederike Saathoff, Dr. Tina Adunka, Dr. Melanie Merk, Dr. Christian Wißkirchen, Dr. Christoph Freier, Dr. Gabriele Wiedemann and Dr. Moritz Rapp).

Thanks to my group „AG Kobold and Endres“: Julius Steffen, Stefanie Völk, Luisa Hofer, Luisa Berdin, Philip Peters, Christopher Lampert, Michael Chaloupka, Simon Grassmann, Daniel Wenk and Susanne Wenk.

I thank Dr. Michael Hristov for answering all my questions concerning FACS analysis.

I thank Dr. Jens Neumann for the patient samples and the good collaboration.

Special thanks to Michael Pirzas for support.

I am deeply thankful to Michael Becker for his patience, support and motivation.

Many thanks to the Klin-Pharm and all Grako members.
Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

Eidesstattliche Versicherung

Küpper, Natascha Jennifer

Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem Thema

Analysis of T cells as potential sources of interleukin-22 in colorectal cancer

selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe.

Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde.

Ort, Datum Unterschrift Doktorandin/Doktorand